NPO Petrovax Pharm and Boehringer Ingelheim continue their work to localise
The project aiming to produce innovative thrombolytic medicines in Russia was launched in June, when NPO Petrovax Pharm and Boehringer Ingelheim signed a joint cooperation agreement in the Chamber of Commerce and Industry of the Russian Federation during a meeting discussing the development of
By the end of 2019, NPO Petrovax Pharm and Boehringer Ingelheim intend to complete the transfer of technologies and to launch
For Boehringer Ingelheim, this is the first localisation project of its kind: Petrovax Pharm will be the world’s second site to manufacture Boehringer Ingelheim’s innovative thrombolytic medications. The facility’s capacity will be enough to fully meet the need for these drugs in Russia.